Company news
RenovoRx, Inc. news in 2024
RenovoRx, Inc.'s news releases, calls and decks from 2024, newest first.
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
December 29, 2024
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
December 10, 2024
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4: 30 p.m. ET
December 9, 2024
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
December 4, 2024
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
November 19, 2024
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
November 13, 2024
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
September 24, 2024
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
September 18, 2024
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
August 26, 2024
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
August 13, 2024
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
July 30, 2024
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
July 7, 2024
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
June 25, 2024
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
June 9, 2024
RenovoRx CEO Issues Update Letter to Shareholders
May 29, 2024
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
May 20, 2024
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
May 13, 2024
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 1, 2024
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
April 17, 2024
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
April 15, 2024
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
April 14, 2024
RenovoRx Announces $11.1 Million at Market Private Placement
April 7, 2024
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
April 4, 2024
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
March 11, 2024
RenovoRx Highlights Key Leadership Promotions
March 7, 2024
RenovoRx CEO Issues Letter to Shareholders
February 5, 2024
RenovoRx Closes $6.1 Million Private Placement
January 28, 2024